
## A phase 2 multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction



variables favoring ATG response

shorter disease duration % Ki67 on CD4+ T-cells % terminal memory CD8+ cells variables associated with ATG failure

longer disease duration bone marrow fibrosis more than 2 prior MDS therapies